Remibrutinib in Sjogren's Syndrome Dr. Putman reports on abstract 1113 presented at #ACR22 Convergence Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study https://t.co/ymFkNWPaXo https://t.co/0k6vLIu0Ku